Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed

Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shared the long-term findings from the pivotal CARTITUDE-1 trial, and highlighted future directions for CAR T-cell therapy in this disease.

Related Keywords

Massachusetts , United States , Dana Farber Cancer Institute , Boston , Nikhilc Munshi , , Novartis , Amgen , Jerome Lipper Multiple Myeloma Center , Harvard Medical School , Correlative Science , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Adaptive Biotechnologies , Karyopharm Therapeutics ,

© 2025 Vimarsana